Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6112147 | 0.75 | DYRK1A (0.36) | DYRK1A | |
| SCHEMBL2040833 | 0.75 | DYRK1A (0.43) | DYRK1A | |
| SCHEMBL2977356 | 0.75 | DYRK1A (0.36) | DYRK1A | |
| SCHEMBL12687213 | 0.75 | DYRK1A (0.36) | DYRK1A | |
| SCHEMBL2040956 | 0.75 | DYRK1A (0.36) | DYRK1A | |
| SCHEMBL9928532 | 0.71 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL11306761 | 0.71 | DYRK1A (0.37) | DYRK1A | |
| SCHEMBL5356031 | 0.71 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL22430373 | 0.71 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL31187477 | 0.68 | DYRK1A (0.35) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1485390-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7091347-B2 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | CHEN JIAN J | 2006-04-20 | — | — | US | disclosed |
| EP-1485390-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | F. Hoffman-la Roche AG (CH) | 2004-12-15 | — | — | EP | disclosed |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC | 2003-11-06 | — | — | US | disclosed |
| WO-2003074530-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAPKAPK2 | DYRK1A 351/4885 |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | DYRK1A 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.